Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002051 · ClinicalTrials.gov registry record · NA
Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection
A NA study, sponsored by Immunobiology Research Institute.
- Completed
- Registry status
- NA
- Development phase
NCT00002051: Completed NA study, sponsored by Immunobiology Research Institute.
NCT00002051 is a NA study that has completed, run by Immunobiology Research Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002051, a NA study, has completed, sponsored by Immunobiology Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
Examine the ability of thymopentin (Timunox) to: Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.
Interventions
- DRUG Thymopentin
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002051 record still lists
NCT00002051 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Thymopentin is the first listed.
NCT00002051 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002051 about?
NCT00002051 is a clinical study titled "Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection". Examine the ability of thymopentin (Timunox) to: Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.
What is the current status of trial NCT00002051?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002051?
The interventions under investigation include: Thymopentin (DRUG).
Who is sponsoring clinical trial NCT00002051?
This trial is sponsored by Immunobiology Research Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.